Latest " Taro Pharmaceutical Industries Ltd." News Stories

03:51 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for " Taro Pharmaceutical Industries Ltd." found in our extensive news archives from over 250 global news sources.

More Information about  Taro Pharmaceutical Industries Ltd. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about  Taro Pharmaceutical Industries Ltd. for you to read. Along with our medical data and news we also list  Taro Pharmaceutical Industries Ltd. Clinical Trials, which are updated daily. BioPortfolio also has a large database of  Taro Pharmaceutical Industries Ltd. Companies for you to search.

Showing "Taro Pharmaceutical Industries" News Articles 1–25 of 11,000+

Sunday 16th December 2018

Mochida Pharmaceutical Co Ltd 4534 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryMochida Pharmaceutical Co Ltd Mochida is a pharmaceutical company that develops, manufactures and markets drugs and diagnostic regents. The company's drugs are used for the treatment of arteriosclerosis obliterans, hyperlipidemia, hypertension, angina pectoris, endometriosis, mycosis, thrombosis, acute circulatory failure, acute pancreatitis, acute myocardial infarction, depression and depr...

Ligand Pharmaceuticals Inc LGND Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryLigand Pharmaceuticals Inc Ligand develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted prodrug technologies to assist companies in securing prescription drug approvals. It p...

Aplastic Anemia Pipeline Review, H2 2018 [Report Updated: 13112018] Prices from USD $2000

Aplastic Anemia Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia Pipeline Review, H2 2018, provides an overview of the Aplastic Anemia Hematological Disorders pipeline landscape.Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fati...

Saturday 15th December 2018

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018 [Report Updated: 28092018] Prices from USD $3396

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018SummaryThis report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulcers, venous leg ulcers, burns and scars, and features dormant and dis...

Alcami Corp Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryAlcami Corp Alcami, formerly AAIPharma Services Corp/Cambridge Major Laboratories, Inc AAI/CML is contract development and manufacturing company CDMO that offers a comprehensive range of pharmaceutical development and manufacturing services to small and midsize pharmaceutical and biotechnology companies across the world. Its key services include active pharmaceutical ingredients API develop...

Takeda Pharmaceutical Co Ltd 4502 Financial and Strategic SWOT Analysis Review [Report Updated: 05122018] Prices from USD $125

Takeda Pharmaceutical Co Ltd 4502 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that ...

Pharmaceutical Development is discussed on "Information Matrix" with Laurence Fishburne

An upcoming episode of the popular program will discuss the process of bringing pharmaceuticals to market. FORT LAUDERDALE, Fla. (PRWEB) December 15, 2018 On an upcoming episode of “Information Matrix” opened by Laurence Fishburne, the topic of discussion will be Pharmaceutical Development in the United States. The process of bringing a pharmaceutical drug to the market is a long and often ar...

Friday 14th December 2018

Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications

Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved HERZUMA

Systems Oncology Announces Pipeline of Innovative Drugs Emerging from the Use of Artificial Intelligence

Dr. Spyro Mousses, CEO of Systems Oncology, LLC, announced Systems Oncology’s diversified pipeline of innovative oncology programs discovered with the help of Artificial Intelligence at the AIMed North America Conference in Dana Point, California. Systems Oncology, an AI-based biopharmaceutical company, utilizes computational tools and machine l...

Otsuka’s Frank Czerwiec Joins Goldfinch Bio as Chief Medical Officer

Goldfinch Bio has appointed Frank Czerwiec to serve as its chief medical officer. Czerwiec joins the Cambridge, MA, biotech from Otsuka Pharmaceutical Development & Commercialization, where he was most recently vice president, global clinical development leading the company’s cardio-renal and metabolic/medicine group. Goldfinch is developing treatments for genetically driven kidney diseases.

PDA Announces Diverse 2019 Board of Directors

PDA's 2019 Board of Directors is one of them of the most diverse boards in the pharmaceutical industry. BETHESDA, Md. (PRWEB) December 14, 2018 The Parenteral Drug Association (PDA) today announced the results of its Board of Directors Election for the term beginning January 1, 2019. In the fall of 2018, PDA’s 10,500 members had an opportunity to participate in the election of new directors...

BIO Statement on Hatch-Waxman Integrity Act of 2018

Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the Hatch-Waxman Integrity Act of 2018: “For almost 40 years, the groundbreaking law known as the Hatch-Waxman Act (HWA) has been highly successful in spurring the development of life-saving new treatments while at the same ...

Janssen Submits sNDA for Xarelto to Prevent Venous Thromboembolism in Acutely Ill Patients

NewsIf approved, it will add to Xarelto's five existing Venous Thromboembolism indications, including treatment of deep vein thrombosis and pulmonary embolism.

TripleTree Advises Consolo Services Group on Acquisition by WellSky

TripleTree, LLC, a strategic advisor and merchant bank serving innovative companies in healthcare, is pleased to announce that its client, Consolo Services Group, a portfolio company of Bluff Point Associates and leading provider of fully-integrated, web-based health IT solutions for the hospice and palliative care industries, has been acquired by WellSky,...



Drugs companies asked to maintain a six-week stockpile for six months in the event of 'no-deal' Brexit

Pharmaceutical companies have been asked to maintain a rolling six-week stockpile of medicines for six months in the event of a ‘no-deal’ Brexit, the government has confirmed.

Rusan Pharma launches DCGI approved Aposan to treat patients with Parkinson's disease

Rusan Pharma, a fully integrated global pharmaceutical company specializing in the treatment of 'Addiction and Pain Management', announced the launch of DCGI approved Aposan (apomorphine hydrochloride (HCl)

Orexo regains rights to Zubsolv in all countries outside US

Orexo AB, the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, announces that the company will regain the rights to Zubsolv (buprenorphine and naloxone sublingual tablet)

Predictions of early responses in paediatric acute lymphoblastic leukaemia

Researchers have identified markers of pediatric acute lymphoblastic leukaemia to predict early relapses by testing levels of nucleotide excision repair... The post Predictions of early responses in paediatric acute lymphoblastic leukaemia appeared first on European Pharmaceutical Review.

bioLIVE China 2019 to be Newly Upgraded to Lead the Development of Bio-Pharma Technology in Asia

SHANGHAI, Dec. 14, 2018 /PRNewswire/ -- The bio-pharma industry has entered the new stage of rapid development in recent years with the continuous development of cutting-edge biological technology and the emergence and marketing of new targeted drugs and cell therapies. From the perspective of global market size, sales of the global biotech drugs are expected to account for more than one third of ...

Pharmacists on ethnicity, pay and career progression

Julia Robinson summarises the pertinent themes discussed during The Pharmaceutical Journal’s Twitter chat held on Wednesday 12 December 2018.

Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis

Regentys Extracellular Matrix Hydrogel (ECMH™) Advances Regenerative Medicine Approach for Inflammatory Bowel Diseases Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted Europea...

Driven by China Biopharm Industry, Cell Culture Market to Reach $6.2 Billion in 2022: Report

The global market for cell culture products for use in the research, development, and production of biotherapeutic drugs is forecast to reach $6.2 billion in 2022, according to Kalorama Information. NEW YORK (PRWEB) December 14, 2018 Key factors impacting market demand include healthy growth in the production of biopharmaceuticals, the increasing availability of biosimilar products, the continued...

US FDA to improve drug quality through vigilant oversight of data integrity and GMP

Ensuring the safety of our nation's drug supply is a cornerstone of our consumer protection mission. Overseeing the quality and safety of pharmaceutical manufacturing is key to these efforts.

Tilray® Invests C$7.5M in Québec-Based Cannabis Producer ROSE Lifescience Inc.

High Park enters into sale, supply, distribution and marketing agreement with ROSE as its exclusive partner in Québec Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production and distribution, today announced an investment in Québec-based cannabis producer, ROSE LifeScience Inc. (“ROSE”) and an exclusive sale, supply, distribution and ...

Quick Search


News Quicklinks